• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CUV
Click for more information
1.85% $13.28

CLINUVEL PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $741.1M  ! watchlist Created with Sketch. Add to my watchlist

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.59pm 15/11/2024 (20 minute delay) ?
Day
Open $13.55   Day High $13.62   Day Low $13.25
Daily Volume 86459
Bids   Sellers
Number Price Volume   Number Price Volume
1 $13.28 227   1 $13.42 228

Directors & Senior Management

Dr. Philippe J. Wolgen Chief Executive Officer, Managing Director, Executive Director
Mr. Peter Vaughan Chief Financial Officer
Dr. Dennis J. Wright Chief Scientific Officer
Ms. Claire Newstead-Sinclair Company Secretary
Prof. Jeffrey V. Rosenfeld Non-Executive Chairman of the Board
Dr. Pearl E. Grimes Non-Executive Director
Mr. Matthew Pringle Non-Executive Director
Mr. Guy van Dievoet Non-Executive Director
Dr. Karen A. Agersborg Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$13.28 		Change
-0.250(1.85%) 		Mkt cap ! $741.1M
Open High Low Value Volume
$13.55 $13.62 $13.25 $1.157M 86.45K

Buyers (Bids)

No. Vol. Price($)
1 227 $13.28
 

Sellers (Offers)

Price($) Vol. No.
$13.42 228 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
$13.37 		  Change
-0.250 ( 1.19 %)
Open High Low Volume
$13.55 $13.56 $13.25 7938
Last updated 15.59pm 15/11/2024 ?

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.